12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 11.1% to $1.3 during Tuesday’s after-market session. The company’s market…
Immuneering Announces First Patient Dosed In Its Phase 1/2a Trial Of IMM-6-415 To Treat Advanced Solid Tumors With RAF Or RAS Mutations
- Deep Cyclic Inhibitor of the MAPK pathway demonstrated strong tumor growth inhibition in preclinical studies of RAF or RAS mutant tumors, both as monotherapy and in combination -
- Phase 1 portion of the Phase 1/2a
Immuneering Receives FDA Fast Track Designation For IMM-1-104 In Pancreatic Cancer
– Fast Track designation has the potential to accelerate lead asset IMM-1-104's path to U.S. FDA submission for pancreatic ductal adenocarcinoma – – Company expects multiple readouts from its Phase 1/2a clinical
12 Health Care Stocks Moving In Tuesday’s Intraday Session
Gainers Fresh2 Group (NASDAQ:FRES) stock rose 28.4% to $1.22 during Tuesday’s regular session. The market value of their…
Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity For IMM-1-104 And IMM-6-415 At AACR-NCI-EORTC Conference
– Expanded benchmarking of IMM-1-104 as a single agent across more than 190 patient-aligned models in humanized 3D-tumor growth assays demonstrated high sensitivity in a wide range of MAPK-driven tumor types, including
4 Analysts Have This to Say About Immuneering
Analysts have provided the following ratings for Immuneering (NASDAQ:IMRX) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Expert Ratings for Immuneering
Immuneering (NASDAQ:IMRX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Analyst Doubles Immuneering Price Target Citing Initial Data Validation
Tuesday, Immuneering Corporation (NASDAQ:IMRX) announced initial pharmacokinetic (PK), pharmacodynamic (PD), and safety data from the Phase 1 trial of IMM-1-104. IMM-1-104…
Benzinga’s Top Ratings Upgrades, Downgrades For April 19, 2023
Upgrades For Tapestry Inc (NYSE:TPR), OTR Global upgraded the previous rating of Mixed to Positive. For the second…
What 7 Analyst Ratings Have To Say About Immuneering
Within the last quarter, Immuneering (NASDAQ:IMRX) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…